ArticleKidney medicine2023
Home Subcutaneous Magnesium Infusion in Refractory Hypomagnesemia: A Case Report.
Article in Kidney medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 3 citations in OpenAlex.
- Cerebellar Syndrome From Proton Pump Inhibitor-Induced Hypomagnesemia: Two Reversible but Relapsing Cases.Case reports in otolaryngology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
We describe a patient with renal magnesium wasting and prolonged, symptomatic hypomagnesemia that was refractory to oral therapies and intermittent intravenous infusion who achieved near-normal serum magnesium levels with subcutaneous magnesium infusions. A woman in her 40s was seen in nephrology clinic for evaluation and management of severe, chronic hypomagnesemia because of renal magnesium wasting in combination with frequent diarrhea. Clinical manifestations associated with hypomagnesemia included muscle weakness, cognitive impairment, and frequent seizures. Her hypomagnesemia had persisted for more than 20 years despite maximal oral magnesium supplementation and frequent intravenous magnesium infusions. To provide slower delivery of parenteral magnesium, she was prescribed 2 g/d of magnesium sulfate, delivered subcutaneously. This was well tolerated, rapidly normalized her serum magnesium levels, and improved her symptoms. We briefly discuss modalities used for treatment of hypomagnesemia, including shortcomings of intravenous therapy and limited literature discussing efficacy and tolerability of subcutaneous infusions. This case report demonstrates the efficacy and safety of subcutaneous magnesium infusions in a patient with refractory hypomagnesemia and suggests that subcutaneous infusion may be safe and effective for treatment of refractory hypomagnesemia in other patients with urinary magnesium wasting.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.